Buntanetap
Buntanetap (posiphen, ANVS401)
Also known as: Posiphen, ANVS401
An oral drug that lowers production of amyloid, tau and alpha-synuclein at once, now in an 850-patient Alzheimer's Phase 3 with a symptomatic readout due early 2027.
Overview
Buntanetap (Annovis Bio) inhibits translation of three neurotoxic proteins rather than clearing one of them after the fact. A Phase 2/3 was published in 2026, and the pTau217-confirmed Phase 3 fully enrolled in July 2026. The symptomatic endpoint reads out in the first quarter of 2027 and the disease-modification endpoint in 2028. Earlier Parkinson's results were mixed.
Mechanism of action
Inhibits the iron-responsive-element-regulated translation of APP, tau and alpha-synuclein mRNAs, reducing levels of all three proteins.
Key studies & citations
- Human2026
Buntanetap Phase 3 in early Alzheimer's disease
850 patients enrolled; readouts 2027 and 2028.
ClinicalTrials.gov NCT06709014 - Human2026
Buntanetap in early Alzheimer's: Phase 2/3 results
Cognitive signal supporting Phase 3.
Nature Portfolio journal
Frequently asked questions
Is buntanetap an amyloid antibody?
No. It is a small molecule taken by mouth that reduces how much amyloid, tau and alpha-synuclein neurons make.